Market Research

[lussi113]

Multiple Myeloma Market driven by growing cases of plasma cancer across the globe

Global Multiple Myeloma Market: Overview

Cancer begins when the cells in the human body start growing out of control. Nearly in any body part, cells can become cancerous and spread to different parts of the body. Multiple Myeloma is a type of cancer which is formed by malignant plasma cells. The normal plasma cells are basically found in bone marrow and are thus an important part of the immune system. Our immune system is made of various cells working together to combat infections and other different types of diseases. Lymphocytes are the chief cell type in the human immune system. The key lymphocytes are B cells and T cells. B cells mature and convert into plasma cells when they respond to an infection. Plasma cells help in creating the antibodies that enhance the immunity system of the body and kills germs. However, when these plasma cells grow out of control and become cancerous, they are likely to generate a tumor known as plasmacytoma. These tumors are basically formed in the bone, but at times can also be formed in other tissues. If a patient is suffering from just a single plasma cell tumor, it is known as isolated plasmacytoma and if it is more than one plasmacytoma, then it is called multiple myeloma.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1114

The plasma cells in a person’s body suffering from multiple myeloma, tend to crowd out normal blood, thus forming cells resulting in low blood counts. This also leads to anemia which is the lack of red blood cells. Multiple myeloma also leads to the lowering of platelets level in the blood. This further leads to a rise on bruising and bleeding. Another severe condition that a patient develops is leukopenia which is the dearth of the normal white blood cells, thus causing immunity problems. Myeloma further hinders the working of the bones and their strength. It makes them fragile by signaling the new bone or osteoblasts to speed up the bone dissolving process. As a result of this, before a new bone is formed, the old bone breaks. The rising bone breakage also leads to calcium deficiency in the human body. Moreover, abnormal plasma cells fail to protect the human body from severe infections. In the case of multiple myeloma, the normal plasma cells crowd out, failing to produce the antibodies that fight bacteria. The antibodies made by the myeloma cells do not help in fighting infections. It is because the myeloma cells are basically multiple copies of the same plasma cell – all making the exact copies of the same (or monoclonal) antibody. Likewise, the antibodies produced by myeloma cells can also harm the kidneys. This can cause kidney damage and also kidney failure.

The report is a complete analysis of the growth trajectory in terms of the past, present, and future progress and prospects of the global multiple myeloma market. It offers an assessment of the aspects that are expected to impact the growth of the market and the principal trends have also been mentioned in the study. The report also offers a diverse outlook of the competitive scenario of the market by utilizing the value chain and Porter’s five forces analysis. The report highlights the research and development projects, mergers and acquisitions, details on collaborations and licensing. The study provides insights into the marketing strategies, products, and shares of the key players operating in the market.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/multiple-myeloma-market.html

Global Multiple Myeloma Market: Trends and Opportunities

The global multiple myeloma market is likely to be driven by the shift in the lifestyle of consumers and growing cases of plasma cancer across the globe. The rising penetration of cancer drugs such as Revlimid and their amalgamation with the upcoming therapies is expected to bode well for the growth of the global multiple myeloma market. The development of new drugs and investment in research and development projects by government and non-government organizations is further expected to boost the market growth.

Global Multiple Myeloma Market: Regional Outlook

The growing economic development in Asia Pacific and Latin America is expected to provide vendors in the global multiple myeloma market with lucrative growth prospects. With numerous drugs in pipelines, the market North America and Europe are also expected to grow significantly.

Companies Mentioned in the Report

Some of the leading companies in the multiple myeloma market are Onyx Pharmaceuticals, Bristol-Myers Squibb, Novartis, Pfizer, Johnson and Johnson, and Celgene Corporation.

[lussi113]

Artificial Tears Market driven by growing number of cases of dry eye syndrome

Global Artificial Tears Market: Overview

Artificial tears are referred to as lubricants eye drops that are used for treating the irritation and dryness associated with the deficiency in tear production in dry eyes or keratoconjunctivitis sicca. These artificial tears are also used for moistening contact lenses and during eye checkups and examinations. Artificial tears are accompanied by other treatments to treat severe forms of moderate to dry eyes. These tears are designed for the purpose to imitate real tears and treating various eye problems. These eye drops are basically used for the purpose of treating problems caused due to dryness and irritation. These artificial tears are made by employing salts, water, and polymers. However, these tears do not inherit the proteins which are present in real tears. Artificial tears can be purchased in any pharmacy or medical unit. The demand for tear gas varies from country to country based completely on the level of population, disease prone area, geriatric population, and female population.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1116

In the near past, artificial tears have evolved as a potential solution to meet the need of patients who suffer from extremely dry eyes and need to apply artificial in every three hours. For this kind of patients, companies have introduced artificial tear products with non-irritating preservatives or no preservatives at all. Although artificial tears are easily available across the globe, its excessive use also has certain side effects such as vision changes, continued redness, irritation, and eye pain. With the ongoing advances in technology, these issues related to the side-effects have been tried to address with the development of preservative free artificial tear gas.

The market intelligence report is a descriptive overview of the growth trajectory in terms of the past, present, and future progress and prospects of the global artificial tears market. It further presents an evaluation of the aspects that are anticipated to impact the growth of the market and the chief trends. The report also offers a distinct understanding of the competitive scenario of the market by utilizing the value chain and Porter’s five forces analysis. A broad description of the various products circulated in the global and regional markets has also been provided in the study. The publication also highlights the research and development projects, mergers and acquisitions, details on collaborations and licensing. The publication also offers information on the marketing strategies, products, and shares of the key players operating in the market.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/artificial-tears-market.html

Global Artificial Tears Market: Drivers and Restraints

The primary driver of the global artificial tears market is the growing number of cases of dry eye syndrome (DES). This syndrome is basically triggered by the forces such as prolonged exposure to digital displays, chronic conjunctivitis, poor eyelid, scars of eye injury, regular air travels, poor diet, malnutrition, the rise in the level of pollution, dry weather spells, and severe climatic changes. Other factor that is expected to drive the growth of the global artificial tears market is the economic status of consumers in developing regions. As the per capita in several developing countries is low as compared to that of developed countries, the consumption of meagerly priced artificial tear products is expected to rise among them. The growing prevalence of preservative free artificial tears, technological advances, the rising requirement for advanced care for post-surgery dry eyes, the mounting number of mobile and smartphone addicts, and increasing number of people wearing contact lens.

Global Artificial Tears Market: Regional Outlook

The global artificial tears market has been segmented into Europe, Asia Pacific, North America, and the Rest of the World. As a result of the low income status of consumers in Asia Pacific and Latin America and the availability of a wide range and varieties of artificial tear products, the markets in these regions are likely to exhibit potential growth over the coming years. As compared to North America and Europe, Asia Pacific is poised to grow at a higher rate. This growth can be attributed to the rising number of aged population and the growing incidences of DES patients in these regions.

Companies Operating in the Market

The leading companies operating in the market are Allegan Inc., Alcon Inc., Santen Pharmaceuticals Novartis International AG, Bausch & Lomb, McNEIL-PPC, Inc., Advanced Vision Research, Inc., and Abbott Medical Optics Inc.

[lussi113]

Multiple Sclerosis Drugs Market- Positive long-term growth outlook 2016 - 2024

Global Multiple Sclerosis Drugs Market: Overview

The global market for multiple sclerosis drugs is heavily influenced by the significant increase in the patient pool suffering from secondary progressive and relapsing-remitting multiple sclerosis. The augmenting demand for novel potent drugs for the treatment of multiple sclerosis and the presence of a robust drug pipeline are also propelling this market substantially. Over the forthcoming years, the projected commercialization of drugs that are currently in development phase, such as Zinbryta and Ocrelizumab, is likely to reflect greatly on this market.

This research study, prepared using a number of paid and unpaid sources, offers a detailed assessment of the global market for multiple sclerosis drugs. It is a highly dependable business tool, which assists in identifying prominent trends and growth prospects of this market at both, regional as well as international level. It also presents quantitative and qualitative insights into the competitive landscape of this market by profiling the key enterprises on the basis of their market shares, latest development, business strategies, product details, revenue structure, and contact information. It further performs a SWOT analysis of each of the market players that reveals their potential growth trajectory. In the report, the worldwide market for multiple sclerosis is analyzed on the basis of the drug class, mode of administration, and geographical spread of this market for a coherent understanding.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1130

Global Multiple Sclerosis Drugs Market: Trends and Opportunities

Of late, the escalating prevalence of multiple sclerosis and the extensive research and development pipelines are the prime driving force behind the tremendous growth of the global market multiple sclerosis drugs. In addition to this, the increased research in the field of multiple sclerosis for the development of innovative therapies is likely to boost this market significantly in the forthcoming years.

On the other hand, patent expiry of various blockbuster drugs may create an obstruction in the growth trajectory of this market. Besides, the stringent regulatory hurdles are also projected to restrict this market from rising steadily. However, advancements in biomedical science will create a lucrative opportunity for drugmakers in the near future. The rising mergers and acquisitions between these vendors and the ongoing product launches will also influence this market greatly in the coming years.

Immunomodulators (Avonex/Plegridy, Copaxone, Gilneya, Betaseron/Extavia, Tysabri, Rebif, Tecifidera, and Ampyra) and immunosuppressant (Ocrelizumab, Lemtrada, Aubagio, and Zinbryta) have emerged as the most preferred drug classes used for the treatment of multiple sclerosis and its associated symptoms. Researchers expect this scenario to remain so over the next few years.

Oral, injectable, and intravenous have been identified as the main modes of administration of multiple sclerosis drugs across the world. The demand for oral drugs is higher and is expected to remain so over the forthcoming years.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/multiple-sclerosis-drugs.html

Global Multiple Sclerosis Drugs Market: Geographical Analysis

North America, Europe, Asia Pacific, and the Rest of the World are considered as the predominant geographical segments of the global market for multiple sclerosis drugs. Among these, North America dominates the overall market, thanks to the presence of a state-of-art medical and healthcare infrastructure. In this region, the U.S. has acquired the topmost position and is trailed by Canada.

Europe and Asia Pacific are also experiencing a robust rise in the demand for multiple sclerosis drugs. In Europe, Spain, Germany, France, Italy, and the U.K. have been leading the market for multiple sclerosis drugs. China, Japan, and India are key contributors to the market for multiple sclerosis drugs in Asia Pacific. The Asia Pacific market is likely to exhibit a higher growth rate than other regional markets over the next few years, thanks to the increasing construction manufacturing and research facilities of a number of leading manufacturers of multiple sclerosis drugs.

Companies mentioned in this report

At the forefront of the global market for multiple sclerosis drugs are Biogen Idec, Bayer Healthcare, Teva Pharmaceuticals, Pfizer, Merck, Sanofi-Aventis, and Novartis. The ample presence of unmet needs and the growing demand for highly effective and fast-acting drugs are expected to prompt drugmakers to modify their existing product portfolio in the near future.

[lussi113]

Therapeutic Vaccines Market- Technological advancements to Watch Out for Near Future; Global Industry Analysis 2024

Global Therapeutic Vaccines Market: Overview

The global market for therapeutic vaccines is witnessing a phase of significant growth. Thanks to the efficiency of these vaccines, an upsurge in their demand is likely to continue over the next few years.

Therapeutic vaccines trigger and build up the immune response of the body so that it can act against the disease and are administered for the treatment of specific medical conditions. With ongoing advancements, these vaccines have expanded the periphery of chronic disease therapeutics, which consequently, is likely to add to the growth of this market over the forthcoming years.

The lengthy approval period, on the other hand, may distract this market from rising steadily in the near future. However, with an ever-expanding body of evidence about the efficiency of therapeutic vaccines, there is ample to look forward to in the worldwide market for therapeutic vaccines space.

This research study on the global therapeutic vaccines attempts to present a detailed assessment of this market on the basis of its existing status and past performance. The key trends and the growth opportunities in this market have also been examined thoroughly in this research report to identify the market’s future status.

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1133

Global Therapeutic Vaccines Market: Trends and Opportunities

The global market for therapeutic vaccines is heavily influenced by the significant rise in the prevalence of various chronic diseases, such as cancer, HIV, and cardiovascular diseases. The alarming increase in the need for efficient treatment has shifted the focus towards therapeutic vaccines across the world. A number of pharmaceutical companies have begun the research to develop novel vaccines for several diseases, such as breast cancer, lung cancer, Alzheimer. Although these developments are still in pipeline and are yet to be commercialized; they point towards a thriving future of the worldwide market for therapeutic vaccines.

As of now, several multinational drugmakers have taken an active lead in the production therapeutic vaccines, opening new growth avenues for this market. Among the pioneers, is Provenge, the first FDA-approved immunotherapy drug, developed for prostate cancer treatment. Since the approval of this drug in 2010, there is no looking back for this market. A number of vaccines have been developed and are in the pipeline since then, exhibit lucrative potential for the market.

On the other hand, together with huge research and development investments and lengthy approval processes, the developers of therapeutic vaccines have to deal with non-existent reimbursement policies for these vaccines too, which acts as a massive drawback for this market. However, in the view of the immense potential presented by therapeutic vaccines, the regulatory bodies across the world are trying to accelerate the policy formulation processes, which if implemented, will reflect positively on the global market for therapeutic vaccines in the near future.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/therapeutic-vaccines-market.html

Global Therapeutic Vaccines Market: Geographical Analysis

North America, Europe, Asia Pacific, and the Rest of the World are considered as the prominent geographical segments of the worldwide market for therapeutic vaccines. With the presence of an advanced medical and healthcare infrastructure, North America has surfaced as the leading contributor to this market. The augment in the funding for the increase in research and development activities is likely to boost this regional market further, ensuring its lead over the forthcoming years.

Europe and Asia Pacific are also witnessing a robust rise in the demand for therapeutic vaccines on account of the growing prevalence of various diseases. Europe, which currently stands at the second position, is likely to gain significantly from the technological advancements of the products in the near future. Asia pacific, on the other hand, is expected to benefit from the rising awareness among consumers pertaining to therapeutic vaccines and their advantages over the years to come.

Companies mentioned in this report

The global market for therapeutic vaccines demonstrates a highly competitive and fragmented structure. Merck and GlaxoSmithKline have emerged as the leading participants in this market, thanks to their strong pipeline of therapeutic vaccines. These companies are likely to outperform their competitors over next few years, states the research report. Sanofi-Pasteur, Cytos Biotechnology AG, Intellect Neurosciences, Agenus Inc., Celtic Pharma, Novartis, Bavarian Nordic, Dendreon Corp., Pfizer, and Transgene are some of the other important players operating in this market.

[lussi113]

Musculoskeletal Diseases Market Evolving Industry Trends and Insights 2016 - 2024

Global Musculoskeletal Diseases Market: Overview

Of late, the global musculoskeletal diseases market has been witnessing a tremendous rise in its size as well as valuation. Researchers predict this scenario to remain so over the forthcoming years, thanks to a substantial increase in the prevalence of musculoskeletal disorders across the world. In addition to this, the ample presence of unmet medical needs, specifically in emerging economies, will boost the demand for musculoskeletal disease therapeutics in the near future.

Going forward, the market will also be influenced by the increasing need for the development of drugs that can enhance the bone density and rebuild the lost bone and its strength, fueled by the absence of a proper cure for psoriatic arthritis.

In this research report, the global musculoskeletal diseases market has been examined with a microscopic view. It attempts to present an in-depth assessment of this market on the basis of its past performance and its current status. The recent trends and the growth opportunities within this market have also been studied thoroughly to determine its future status in this market study.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1141

Global Musculoskeletal Diseases Market: Trends and Opportunities

Rheumatoid arthritis, osteoporosis, osteoarthritis, psoriatic arthritis, fibromyalgia, and ankylosing spondylitis are the main musculoskeletal diseases prevalent across the world. Among these, rheumatoid arthritis has been registering a higher prevalence rate and thus, has emerged as the market leader. This chronic inflammatory autoimmune disease is highly prevalent among adults within the age group of thirty to sixty years. With the increasing base of geriatric population, researchers expect this segment to remain dominant over the next few years.

The prime type of molecules used in the production of musculoskeletal disease therapeutics are biologics and small molecules. The biologics segment has acquired a larger share in the overall market. The complex structure of biologics, which does not permit easy identification or characterization, is the main factor behind the growth of this segment. However, other characteristics, such as thermo-labiality and susceptibility to microbial contamination, may limit the adoption of biologics to some extent in the years to come.

Muscle relaxants, anti-inflammatory drugs, analgesics, immunosuppressives, antipyretics, and corticosteroids have surfaced as the most demanded drugs for the treatment of musculoskeletal diseases across the world and are expected to experience strong growth over the next few years.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/musculoskeletal-diseases-market.html

Global Musculoskeletal Diseases Market: Geographical Analysis

North America, Asia Pacific, Europe, and the Rest of the World have been identified as the prominent geographical segments of the global musculoskeletal diseases market. According to researchers, North America, which has been dominating this market since the past few years, is likely to retain its position in the near future. The increased uptake of the existing biologic drugs for the treatment of various musculoskeletal diseases, the introduction of novel biologics, and the enhanced access to medical and healthcare facilities are some of the factors that are expected to drive the North America musculoskeletal diseases market in the coming years.

In addition to this, the essential healthcare benefits offered by employer-sponsored health insurance plans and the increasing investments by vendors in innovative and cost efficient drugs are also projected to support this regional market over the next few years.

Companies mentioned in this report

A large pool of players dominates the global market for musculoskeletal diseases, owing to which, this market demonstrates a highly fragmented and competitive landscape. At forefront of this market are AbbVie, Amgen, Johnson & Johnson, F. Hoffmann-La Roche, Pfizer, and Eli Lilly.

To gain a competitive advantage, these companies are aggressively focusing on developing cost-competitive drugs that are easy to administer and stimulate bone building effectively. The dearth of appropriate therapies and drugs are likely to create a lucrative growth opportunity for vendors in the near future.

Eisai, 3SBio, AbGenomics International, AB Sciences, Ablynx, Akron Molecules, Adheron, Alder BioPharmaceuticals, Ampio Pharmaceuticals, Astellas, Antares Medical Services, AstraZeneca, Biocad, Baxter, Bioiberica, Bone Therapeutics, Edding Pharm, Boehringer Ingelheim, Can-Fite BioPharma, Celltrion, Celgene Corp., Cellular Biomedicine, ChemoCentryx, Cerapedics, Chugai Pharmaceutical, Daiichi Sankyo, Coherus Biosciences, Dong-A ST, Eupraxia Pharmaceuticals, and GlaxoSmithKline are some of the other prominent participants of this market.

[lussi113]

Advances in Protein Market- Increasing adoption of protein drugs are driven the Market growth

Advances in Global Protein/Antibody engineering Market: Overview

Protein/antibody engineering has emerged as a well-developed discipline in the pharmaceutical industry. With efficient discovery methods, production techniques, and modification strategies, it is bringing forth a number of clinically examined and marketed therapeutics. Besides, the focus of the intensive research in this field has shifted to the clinical deployment of antibodies, thanks to the realization of the enduring goal of the manufacturing of fully human monoclonal antibodies.

In the pharmaceutical industry, antibodies have acquired a massive market share and are showing potential for tremendous growth in the near future. With the introduction of novel technologies, the advances in the global market for protein/antibody engineering are more evident. As protein engineering provides flexibility in designing and engineering of new and required antibodies, this factor is projected to boost this market significantly over the next few years. The rising concerns over health and the increasing prevalence of various diseases, such as cancer and other chronic medical conditions, are also anticipated to provide lucrative opportunities for market growth in the years to come.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=879

This research report on the global market for protein/antibodies engineering provides a detailed and unbiased market evaluation, taking the advancements in this market into consideration. Researchers have also studied the key trends, opportunities, and the growth potential of this market in order to forecast its future status in this market report.

Advances in Global Protein/Antibody engineering Market: Trends and Opportunities

The increasing adoption of protein drugs in comparison with non-protein ones and the augmenting prevalence of lifestyle diseases are having a substantial influence on the need for protein/antibody engineering, leading to a significant growth in the worldwide market for protein/antibody engineering. Apart from this, the rise in funds for protein/antibodies engineering and the decrement in the overall cost and time incurred in drug discovery are also expected to boost this market over the forthcoming years. However, the lack of skilled professionals and the high cost and maintenance required for tools and instruments utilized in protein/antibody engineering may create obstacles in the rise of this market to some extent in the near future.

With the growing demand for monoclonal antibodies, erythropoietin, insulin, interferon, growth hormones, vaccines, colony stimulating factor, interleukins, coagulation factor, enzyme replacement, follicle stimulating hormones, and other protein types, the global market for protein/antibody engineering is likely to witness strong growth in future. Among all the protein types, the monoclonal antibodies segment is anticipated to acquire a greater share in this market in the coming years.

Among the two technologies, namely, rational product design and irrational product design, the demand for the former has been higher than the latter and the scenario is expected to remain so over the next few years.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/advances-in-protein-antibody-engineering.html

Academic research institutes, biotechnology companies, pharmaceutical enterprises, and contract research organizations have emerged as the key end users of protein/antibody engineering across the world. Pharma and biotech companies have been reporting a greater demand for protein/antibody engineering than others and are projected to continue this trend over the forthcoming years, thanks to the technological advancements in protein/antibody engineering and the rise in research and development budgets in the pharmaceutical industry.

Advances in Global Protein/Antibody engineering Market: Geographical Analysis

In terms of the geography, the worldwide market for protein/antibody engineering has been classified into Asia Pacific, Europe, North America, and the Rest of the World. North America has been dominating this market and is trailed by Europe. The presence of a state-of-art medical and healthcare infrastructure and the early adoption of technologies are boosting both the regional markets significantly. Asia Pacific is also projected to register a considerable rise in this market over the forthcoming years.

Companies mentioned in this report

With intense competition between players, the global market for protein/antibody engineering demonstrates a highly competitive landscape. Emerald Bio, Precision Antibody, ProSci Inc., Fusion Antibodies, GenTarget Inc., BioXcell, ImaginAb, IBL International, and Covalab are some of the leading players operational in this market. These enterprises mostly rely on product innovation and advancements in technologies for the development of their businesses. However, a shift in their focus towards strategic alliances, mergers, and acquisitions can be witnessed in the forthcoming years.

[lussi113]

Autacoids and Related Drugs Market- Positive long-term growth outlook 2016 - 2024

Global Autacoids and Related Drugs Market: Overview

Autacoids refer to the biological factors that work like hormones and are released from body cells in response to various types of stimulations to prompt physiological responses such as treatment of a local injury or other ailments. Any imbalance in the release, synthesis, or transduction system associated with these temporarily formed biological agents trigger pathological conditions such as allergy, inflammation, and hypersensitivity. Autacoids antagonists are prescribed for the prevention of such undesirable changes to the body in response to imbalance in the operation of autacoids.

This report on the global market for autacoids and related drugs presents estimates and forecasts regarding the growth prospects of the market on global, regional, and country levels. Predictions regarding the market and its key segments are provided for the period between 2016 and 2024 based on consumption value and revenue prospects, considering 2015 as the base year. The report includes a detailed value chain analysis for all the key market segments with thorough qualitative as well as quantitative data for these segments.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1222

The report also elucidates the key factors expected to have a sizeable impact on the overall development of the global autacoid and related drugs market over the period between 2016 and 2024. As such, key drivers, restraints, trends, regulations, and vendor and competitive landscapes are analyzed. Key growth opportunities in the autacoids and related drugs market on regional as well as global levels are also analyzed in the report. The report also includes a detailed market attractiveness analysis, wherein key applications, product varieties, and region- and country-level markets have been analyzed on the basis of attractiveness for key regional markets.

Global Autacoids and Related Drugs Market: Growth Prospects

The global market for autacoids and related drugs is expected to cross the 100 bn mark by 2018. Rising research and development activities demonstrating the use of autacoids as potential therapeutic immunomodulators for a variety of disease conditions and the increased interest in use of lipid autacoids as important therapeutic agents for treating chronic pain will be the key factors driving the market. The significant rise in cases of chronic pain across the globe and the increased focus of the medical community on the severity of chronic pain and finding effective ways to treat it are expected to make lipid autacoids a key drug candidate for the condition in the near future.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/autacoids-related-drugs.html

Global Autacoids and Related Drugs Market: Segmentation

Autacoids are broadly segmented into polypeptides, decarboxylated amino acids, and eicosanoids. The key varieties of polypeptides in autacoids are vasopressin, angiotensin, vasoactive intestinal polypeptide, plasma kinin, slow reacting substances of anaphylaxis, and substance P. Key varieties of decarboxylated amino acids are serotonin and histamine. The key applications of autacoids and related drugs are treatment of allergies, inflammation, gastric acid secretion, neuroendocrine regulation, chronic pain, cardiovascular diseases, gastrointestinal diseases, and anaphylactic reactions.

The key drug categories related to autacoids include drugs related to lipid-derived autacoids, polypeptide autacoids, drugs related to endothelium-derived autacoids, and biogenic amines. Of these, the segment of biogenic amines is presently the dominant drug category in the autacoids class, accounting for nearly 65% of the overall autacoids market.

In terms of geography, the market has been segmented into regions such as North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Additionally, the report also includes a country-level analysis of the market for autacoids across these regions. Data included in the report combines demand and consumption statistics for key applications and product varieties across key regions and countries.

Global Autacoids and Related Drugs Market: Companies Profiled in the Report

The report provides an exhaustive competitive outlook of the market including vast details such as the share of key companies, product portfolio, business strategies, recent developments, financial overview (wherever applicable), and strengths and weaknesses of key players operating in the global autacoids and related drugs market.

Some of the key companies operating in the global autacoid and related drugs market are Bedford Laboratories, Bristol-Myers Squibb, APP Pharma, Abbott Laboratories, Sanofi-Aventis, Chattem Inc., Xanodyne, AstraZeneca, and Hospira.

[lussi113]

Adjuvants Market: Competitive Dynamics & Global Outlook 2024

Adjuvant oncology treatment is a part of cancer therapeutics, which entails further cancer treatment after the completion of the primary treatment. Its main aim is to reduce the risk of the cancer coming back again. Adjuvant therapy includes radiation therapy, chemotherapy, targeted therapy, hormone therapy, or biological therapy. Oncologists take into consideration various factors, such as statistical evidence, before zeroing in on the suitable adjuvant therapy.

The primary aim of adjuvant therapy is to increase chances of survival of cancer patients by eliminating the risk of cancer relapsing. It is typically provided after treatment of various kinds of cancers, such as colon, lung, prostate, breast, and others forms of gynecological cancers through oncological surgeries and adjuvant therapy. However, it is ineffective in cases of renal carcinoma and a few kinds of brain cancer.

The report presents an in-depth overview on the global adjuvants market after extensive research. It utilizes both historical and current data to predict the growth prospects in the market. By segmenting the worldwide market based on various parameters and implementing various analytical tools such as SWOT analysis and Porter’s Five Forces, the report gauges the competitive dynamics prevalent in the market.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1176

Global Adjuvants Market: Trends and Opportunities

The primary growth driver in the global market for adjuvant oncology treatment is the rising instances of cancer worldwide. This, alongside many positive initiatives adopted by governments and insurance companies for reimbursing the treatment cost of cancers, has provided a major fillip to the market. Further, an increasing thrust on research initiatives and efforts to uncover more maladies that could be treated with adjuvant therapy are slated to propel the market growth in the upcoming years.

The report classifies the overall market for oncology adjuvants depending upon the applications and various types of cancers they are used to treat. By doing so, the report tries to understand where maximum opportunity lies in the market. Based on applications, for example, it segments the market for adjuvants into immunotherapy, chemotherapy, radiotherapy, and others. Based on diseases treated through adjutants, it classifies the market into sarcoma, breast cancer, Hodgkin’s lymphoma, colorectal cancer, glioblastoma, prostate cancer, lung cancer, and ovarian cancer. Breast cancer accounts for a major chunk of the revenue in the market at present and going forward, it would only up the current figures. In terms of growth rate, however, colorectal cancer will likely outshine all other segments.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/adjuvants-market.html

Global Adjuvants Market: Regional Outlook

Geography-wise, the report divides the market into Asia Pacific, Europe, North America, and the Rest of the World. Among them, Europe and North America are the dominant markets for adjuvants. This is because of the high prevalence of cancer in the two continents. Other factors boosting these markets are the developed healthcare facilities, favorable reimbursements policies, and the greater means of people to spend on better quality healthcare. Knowledge of the disease and its various treatments is also at the forefront of driving the growth of the two regional markets. Corroborating the fact is the finding of World Health Organization (WHO), which states that about 75% countries worldwide have reported having generally available cancer treatment services that include cancer surgery, subsidized chemotherapy and cancer centers or departments. In Europe, an impressive 90% of countries reported having these cancer treatment services generally available.

Asia Pacific follows North America and Europe in terms of market share. The emerging economies of India and China with their massive populations are major growth drivers in the region. Rising instances of cancer and rapidly developing healthcare infrastructure, coupled with the rise in medical tourism in the region, have stimulated the growth of the market so far. In the near future too, the region will exhibit promising growth on account of a flurry of research initiatives due to the availability affordable human resources and helpful government policies.

Companies Mentioned in the Report

To present a proper assessment of the existing competition in the global market, the report has profiled some of the key companies operating in the market such as Eli Lilly Co., Amgen, Inc., BMS, Biogen, Sanofi, AstraZeneca PLC, and Pfizer, Inc. It studies the sales, revenues, market shares, and growth prospects of each of the players, besides throwing light on their key strategies.

[lussi113]

Antipsychotic Drugs Market- Booming Trend in Pharmaceutical Industry by 2024

Global Antipsychotic Drugs Market: Overview

The global market for antipsychotic drugs is witnessing significant traction owing to the global rise in prevalence of psychotic disorders such as bipolar disorder, schizophrenia, delusions, hallucinations, and very severe depression (called “psychotic depression”). Recent studies have stated that antipsychotics are one of the top-selling and most widely prescribed drugs for managing psychotic conditions in the United States. Although earlier prescribed only for such psychotic conditions, a vast variety of antipsychotics are also prescribed as a supplement to antidepressant medications and for routine complaints such as insomnia. Records demonstrate that antipsychotics such as Abilify are outselling other drug varieties and are becoming one of the key and high-profit drug classes of the pharma industry.

This report on the global antipsychotic drugs market presents a thorough overview of the present state of the market, growth dynamics and popular trends of the past years, and predictions regarding the course of growth the market will witness over the period between 2016 and 2024. The report gives in-depth insights about the factors that will have the most influence on the market’s future growth prospects, including market drivers, restraints, regulatory landscape, and competition among key players.

Download the Industry Fact Sheet by 2024 http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1164

A thorough account of the vendor and competitive landscape of the global antipsychotic drugs market included in the report sheds light on the various opportunities available for new and existing players to gain promising returns on investment in the field of antipsychotic drugs. A SWOT analysis of key vendors allows a clear understanding of the strengths and weaknesses of key market vendors as well as the threats and opportunities ahead of these companies in the global market.

Global Antipsychotic Drugs Market: Drivers and Restraints

Global estimates suggest that over 1.25% of the global population suffers from psychosis and related disorders. This translates into a potential market of about 7.5 mn people as target consumers for antipsychotic drugs. Although the potential consumer base for the market is relatively much smaller than that for diseases such as cancer and diabetes, the high costs of antipsychotic drugs make the market one with promising returns. The market holds immense growth promise for future years as the patient pool of psychotic conditions rises at an alarming rate across the globe. The introduction of newer antipsychotic compounds and the vast funds poured in for research and development activities are also expected to have a significant positive impact on the overall development of the market in the near future.

However, the market is expected to bear the brunt of the concerning rise in cases of over prescription of these drugs even for routine complaints such as insomnia and the increased awareness regarding the severe drawbacks as well as chances of addiction associated with these drugs. The issues have been known to be more intense in developed economies such as North America and a significant rise in strict regulations observing stronger control on the prescription of these drugs and misleading advertisements has been seen in the past few years. The impending patent expirations of several blockbuster drugs and the threat of cheap generics is also adding to worries of companies operating in the global antipsychotic drugs market.

Browse the full Global strategic Business report: http://www.transparencymarketresearch.com/antipsychotic-drugs-market.html

Global Antipsychotic Drugs Market: Segmentation

The report segments the global antipsychotic drugs market on the basis of criteria such as drug classes, target disease, and geography.

On the basis of drug classes, the global antipsychotic drugs market is commonly segmented into: older or first-generation antipsychotics, also called typical antipsychotics or neuroleptics, and newer or second-generation drugs, also called as atypical antipsychotics. Studies have shown that several atypical antipsychotics are useful for a broader spectrum of conditions than older or typical antipsychotics and mostly help treat conditions such as bipolar depression that have not responded to standard medication alone.

The key target diseases for the antipsychotic drugs market are Schizophrenia, psychotic depression, dementia, and bipolar disorder. Of these, Schizophrenia and psychotic depression are expected to account for the dominant share in the market’s revenues over the report’s forecast period. Of the key regional markets analyzed, North America is presently the dominant consumer of antipsychotic drugs and is expected to remain a key regional market owing to the vast and rising patient pool of psychotic disorders.

Some of the key companies operating in the global antipsychotic drugs market are Johnson & Johnson, Pfizer, Eli Lilly and Co., Bristol-Myers Squibb, AstraZeneca, and GlaxoSmithKline.

[lussi113]

Medical Enzymes Technology Market- Growth opportunities in global Industry by 2024

Global Medical Enzymes Technology Market: Overview

Medical applications for enzymes have grown as significantly as those for the industrial sector in the past few years. Vast research activities in the field of enzyme technology and its specific applications in medicines have led to the development of a vast variety of enzymes that have considerable therapeutic uses. Many such enzymes are also being extensively used as important therapeutic agents to treat several life-threatening diseases such as cancer. The enzyme Asparaginase, for instance, has proved to be exceedingly promising for the treatment of acute lymphoblastic leukaemia. It is also presently used for the treatment of several other blood disorders.      

With a vast rise in demand for effective therapeutic agents to treat a vast array of metabolic diseases, the development of new processes to manufacture high value-added and bulk drugs using enzymes as biocatalysts is gaining more focus. As a result, the growth opportunities in the medical enzyme technology market are significantly increasing in number and an increasing number of companies are entering into this space in a bid to exploit the growth opportunities. This report analyzes the prominent trends of past and present times and the numerous growth opportunities that companies in the global medical enzyme technology market need to focus on to gain sustainable returns.

Download the Industry Fact Sheet by 2024 http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1154

A detailed overview of how the recent developments in enzyme technology are influencing the growth trajectory of the global medical enzyme technology market is also included in the report. With the help of meticulous segmentation, the market has been divided into smaller sections to present before the reader a closer analysis of all the key aspects of the market. Complete with qualitative and quantitative data pertaining to these segments, the report makes for an excellent data repository covering the market to an unmatched degree of detail.

Global Medical Enzymes Technology Market: Defining Trends and Drivers

Advances in the field of genetic engineering have unarguably been the most defining development to have influenced the medical enzyme technology market in the past few years. Advancements in the recombinant DNA technology have significantly aided the increased production of enzymes from microorganisms. By being able to transfer the desired enzyme genes from one microbe to another, commonly from the ones with low level synthesis to ones with commercially-viable levels, the desired commercial enzyme is produced in large volumes. This factor will continue to have a significant influence on the overall development of the global medical enzyme technology market in the near future as well.

The global medical enzymes technology market is expected to rapidly expand in the next few years owing to the rapidly expanding array of applications of enzyme technology in medicines, for drug development and for disease diagnostics. Increased funds invested by international pharmaceutical funds towards the research and development of effective therapeutic agents for the treatment of chronic diseases is also a key factor expected to drive the market.

Browse the full Global strategic Business report: http://www.transparencymarketresearch.com/medical-enzymes-technology.html

Global Medical Enzymes Technology Market: Segmentation

A variety of enzymes are used in the field of medicine for applications chiefly including disease treatment, easing metabolism, drug delivery, manufacture of medicines, diagnosis of disorders, biomedical research. Of these, the segment of therapeutic enzymes is presently the dominant application of medical enzymes, accounting for the most significant chunk of the global medical enzyme technology market’s revenue. The use of enzymes in biomedical research is also gaining increasing prominence and is expected to emerge as one of the key applications of medical enzyme technology in the next few years.

In terms of geography, the global medical enzyme technology market is dominated by North America. The region holds the commanding position in the global market owing to factors such as the presence of several international biomedical companies investing vast funds towards R&D activities. Over the report’s forecast period as well, North America is expected to retain its dominant position in the global medical enzyme technology market and account for a significant share of revenues.

However, the market in Asia Pacific is expected to exhibit growth at the most significant pace. Encouraging government policies aiding the development of healthcare infrastructure and medical and biotechnology industries will act as the key factors bolstering the market for enzyme technology for medical applications in the region.

Some of the key players operating in the global medical enzymes technology market are Asahi Kasei Pharma, Agilent Technologies, Thermo Fisher Scientific Inc., Life Technologies Corporation, and Digestive Care Inc.

[lussi113]

Rabies Treatment Market- Evolving Industry Trends and Insights 2016 – 2023

Rabies is a zoonotic viral disease caused due to animal bits. The disease is known to affect domestic as well as wild animals such as bats, skunks, foxes, ferrets, raccoons, cats, or dogs, and infects humans upon contact with saliva of infected animal. Rabies is known to have an incubation period of one to three months. Individuals suffering from rabies show initial symptoms of fever and pain or tingling or burning sensation also called as paraesthesia at the wound site. As the disease progresses through the central nervous system (CNS), patients exhibit hyperactivity, excited behavior, hydrophobia. Rabies can also be paralytic and accounts for approximately 3% of all rabies cases globally according to World Health Organization (WHO). This form is usually misdiagnosed and has slower progression. Muscles near the wound site begin to paralyze; untreated infections lead to coma and cause death.

Download the Industry Fact Sheet by 2023 http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9022

WHO statistics also show that although rabies is prevalent in all continents except Antarctica, more than 95% of the mortalities occur in African and Asian countries. Rabies infections are common in areas where human-animal interaction is more and no proper medical treatment facility is available for treatment. In the U.S. only 55 cases have been identified since 1955 according to Centers for Disease Control and Prevention (CDC). Rapid diagnostic tests are available for diagnosis of rabies. These tests are usually Enzyme Linked Immunosorbent Assay (ELISA) or fluorescent assay technology. Synbiotics Corporation, O.K. SERVIS BioPro, s.r.o., Bio-Rad Laboratories, Inc. and Alpha Diagnostic International are some of the players manufacturing diagnostic kits for rabies.

Browse the full Global strategic Business report: http://www.transparencymarketresearch.com/rabies-treatment-market.html

Novartis and Sanofi are key players in the global rabies treatment market. These companies manufacture prophylactic vaccines for humans. Sanofi’s Imovax Rabies is a human diploid cell vaccine; while Novartis’s RabAvert is a Purified chick embryo cell vaccine. Vaccines are also available for preventing infections in animals. Merial a Sanofi company announced in July 2014 had it has launched PUREVAX Feline Rabies 3 YR vaccine. This is a non-adjuvanted rabies vaccine and provides 3 year immunity. The vaccine has been recommended for immunization of healthy cats 12 weeks and older. Cadila Pharmaceuticals Ltd, is also working on development of new generation rabies vaccine in India. Under-developed countries have initiated mass vaccination of stray dogs to control mortalities.  According to an article published by World Health Organization (WHO) in 2014, Kenya launched a nationwide program for vaccination of dogs. Currently, more than 3,000 dogs in Makueni County have been vaccinated. In September 2014, The Philippines Department of Agriculture (DA), the Australian Government and the World Organization for Animal Health (OIE) launched rabies control project to reduce rabies cases due to dog in the Philippines. Earlier in 2013, massive dog vaccination program was launched, which vaccinated 92,869 dogs and attained 80% coverage according to a press release by World Organization for Animal Health. An article published in The Maravi Post, Malawi also plans to vaccinate 500,000 dogs and cats to curb the rabies crisis. Such preventive programs will help in reducing the prevalence of the disease in lower socio-economic classes. With developing economic conditions and consistent government initiatives, the prevalence of rabies is expected to shrink in the future. Higher prevalence in the Asia Pacific and Africa provides larger customer base for players in the rabies treatment market.    

[lussi113]

Global Nanocapsules Market Driven by Increasing Investment in Nanotechnology

A new research study by Transparency Market Research presents a comprehensive and unbiased overview of the global market for nanocapsules. The report, titled “Nanocapsules Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” is available for sale on the company’s website. 

According to the market study, the increased investment in the nanotechnology sector has boosted the global nanocapsules market to a great extent.

Apart from this, the rising application of nanocapsules in the fields of pharmaceuticals, biomedicals, electronics, molecular and diagnostics, agrochemicals, genetic engineering, environment and wastewater treatments, cosmetic procedures, and consumer goods is also stimulating this market significantly in the global arena.

In addition to this, the novel innovations and discoveries in the field of nanotechnology are likely to drive the growth of the global nanocapsules market during the forecast period. The rising awareness regarding genetic disorders and the increasing incidence of cancer and tuberculosis are also projected to stimulate this market in the coming years, notes the study.

Download the Industry Fact Sheet by 2024 http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5321

The report also analyzes the worldwide nanocapsules market on the basis of its regional spread. North America, Asia Pacific, Europe, and the Rest of the World are the main regional markets for nanocapsules across the world. The North America nanocapsules market is projected to witness significant growth over the forecast period. The investment of approximately US$3.7 bn by the U.S. National Nanotechnology Initiative (NNI) to increase the research and development activities in the field of nanocapsules is the key factor driving the growth of this regional market.

The nanocapsules market in Europe is also expected to experience a substantial rise during the forecast period, owing to the European Union’s investment of around US$1.2 bn in the field of nanotechnology till 2012.

By the same time, Japan also had invested approximately US$750 mn in the nanotechnology industry, stimulating the nanocapsules market in Asia Pacific. Additionally, the increasing pool of patients suffering from cancer and tuberculosis is projected to drive the nanocapsules market over the forecast period.

Browse the full Global strategic Business report: http://www.transparencymarketresearch.com/nanocapsules-market.html

Moreover, the steady demand for technically advanced medical procedures from the healthcare industry in developed as well as developing economies is also expected to boost the global market for nanocapsules in the coming years, says the market report.

Mersana Therapeutics Inc., Makefield Therapeutics Inc., Genetic Immunity Inc., Biophan Technologies Inc., Artificial Cell Technologies Inc., Abraxis, BioDelivery Sciences International Inc., Cornerstone Pharmaceuticals Inc., Keystone Nano Inc., and Nanospectra Biosciences Inc. are some of the key players operating in the global nanocapsules market, states the research study.

[lussi113]

Aged Care Market: New Market Research Report Announced; Global Industry Analysis 2016 - 2023

Most of us want to remain independent and stay in control, but due to growing age our ability starts to decline. Hence, the concept of aged care is introduced, for an easy and better living with proper nursing facility for the higher age group. It is also known as elderly care or eldercare. It emphasizes on the personal and social needs of senior citizens as they need some assistance in their daily activities and medical support who desire to age gracefully. A special act has been taken by the Australian Government for senior citizens known as The Aged Care Act 1997 for people who are unable to live independently of their own. It promises to provides them better and longer living. It is an important distinction that the designing of house, services, activities and employee training of global elderly care falls under the unpaid market sector. The main agenda is to ensure that eldercare services are targeted towards people and areas with the utmost need, it facilitate access to aged care services by those who need them, irrespective of culture, race, language, gender and economic background. Focus is also given on people who are homeless or lives in remote areas and special care is also provided for lesbian, gay, bisexual, transgender and intersex (LGBTI) group. Programs are being adopted for the community based care for older people those are Commonwealth Home Support Program (CHSP) and Home Care Packages Program. These provides coordinated and personalized home care and also offers four classes of package to assist aged people with simple, low, high and very high care needs.

Download exclusive Brochure of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9512

Aged care market has lot to offer for the special service providers who are capable to run long-term as well as short-term aged care home, nutraceutical manufacturers, pharmaceutical manufacturers, senior care furniture manufacturers and real estate companies. Special products are being marketed for aged people such as smart seat hair protector, water proof seat protectors, and bed pads.

It has already made an impact in developed countries like USA, Canada, and Australia. The aged care market is gaining its popularity in the developing countries like China, Singapore and India, as the major proportion of population is above 65 years. More elderly people will take up aged care services in the future rather depending on their families for care and support as younger people are moving to different cities leaving behind their extended family.

Aged care market can be divided on the basis of services and geography. Services can be classified as home care services and residential care services.

In home care services, they provide medical or nonmedical benefits which include personal care, skilled-nursing care, companion facilities, physical therapy and medical social services. It also includes in-home hospice care provider.

In residential aged care, they provides well maintained accommodation for those whose care cannot be met in their own homes and thus needs a special care cell. There are again two categories in residential aged care facilities these are respite care and permanent care. Respite care offers short-term and temporary care in a residential aged care facility and supports both the older people and their care givers to live at home for as long as possible. They provide both high and low care facility. On the other hand permanent care offers tailor made individual needs in the residential aged care facility.

Some of the key players can be divided on the basis of pharmaceutical manufacturer like Pfizer, Novartis, Merck & Co., GlaxoSmithKline, AstraZeneca and Novo Nordisk. On the basis of nutraceutical manufacturer like Alkemists Labs, Asiamerica Ingredients, Inc., Barrington Nutritionals, Nutralliance, Inc., and Proprietary Nutritionals Inc. Senior care furniture manufacturers can be classified as Phoenix Contract, Inc., Flexsteel and Kwalu.

[lussi113]

Fabry Disease Market: Positive long-term growth outlook 2016 - 2023

Fabry disease is an unusual, life-threatening situation with debilitating condition. Fabry disease is an uncommon X-linked inherited disorder. It is caused by the lack of the enzyme alpha galactosidase-A (a-GAL A). It is initiated by the absence of enzyme required to metabolize the lipids, fat-like substances like waxes, oils, and fatty acids. This disease is also known as alpha-galactosidase-A deficiency. Often there is a complete deficiency of a-Gal results in a severe form called the classic Fabry disease. This classic form mostly affects male. Symptoms of this disorder usually appear during childhood or adolescence in both male and female which includes pain that can be either full body or localized known as pricking sensation or numbness (acroparesthesia), gastro hyperactivity, burning sensation in hands, renal inefficiency, cardiac problem and cloudiness of cornea. The pain that is caused by the disease can be treated with anticonvulsants like phenytoin and carbamazepine. Gastric hyperactivity is treated by metoclopramide. Some patient may require dialysis or kidney replacement. However, restricting diet does not help to reduce lipid buildup in cells. The incidence of Fabry disease affects approximately 1 in 40,000 to 60,000 males. Occurrence of this disorder is less frequent in females.

Download exclusive Brochure of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9515

Fabry disease market can be segmented on the basis of its treatment and geography. The type of treatment can be classified as Enzyme replacement therapy (ERT), Alternative therapies and Emergency treatment strategy. ERT has been available for the treatment of Fabry disease since 2001. U.S Food and Drug Administration has approved the ERT for the treatment of Fabry disease. ERT comforts the pain, decreases the lipid storage and preserves organ function in patients with this disorder. Alternative therapy involves palliative and supportive approach for the treatment of Fabry disease. Emergency treatment strategy involves administration of small molecule drugs which are very effective and have a quick response.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/fabry-disease-market.html

The Fabry disease market presents an enormous opportunity in its treatment and cure. The driving factors those have been aiding the growth of The Global Fabry Disease Market. Firstly, there are provision for orphan drugs, diseases with restricted patient population, such as Fabry disease have limited approved drugs. Special benefits are given to this drugs like few years of market exclusivity, tax benefits for clinical testing and exclusion from prescription drug fees in order to recover the research and development expenses of the drug.

Secondly, use of tools like ICD, it is a standard tool for diagnosis purposes. These codes are used for reimbursements by the private organizations or government insurers. The code for Fabry disease is E75.21 ICD-10-CM code. ICD-10 codes have been designed to provide superior specificity and better clinical details. ICD-10-CM codes are also expected to provide complete healthcare data, thus helping in the development of advanced clinical pathways and disease protocols. However, currently there is a lack of disease-modifying therapy in the Fabry disease market but there are lot of potential for the improvement in near future.

Some of the key players in this market are Genzyme Corporation, Shire plc. Amicus Therapeutics. Inc., Synageva BioPharma Corp., JCR Pharmaceutical, ISU ABXIS Co. Ltd., Protalix BioTherapeutics, and Neuraltus Pharmaceuticals, Inc., Biosidus.

[lussi113]

Vitamin Tonics Market driven by increasing health consciousness among the global population

Global Vitamin Tonics Market

Vitamins are among the most important nutrient classes consumed by humans. They carry out several vital physical as well as mental functions in the body. Deficiency of vitamins can lead to severe conditions such as scurvy (vitamin C deficiency), rickets (vitamin D deficiency), and pellagra (vitamin B deficiency). Thus, regular consumption of vitamins is considered a healthy habit.

Though people in less developed regions still regularly fall prey to them, vitamin deficiency disorders are virtually unheard of in the modern world. Even so, the hectic lifestyles of modern consumers don’t allow them to regularly consume a healthy diet. As a result, vitamin supplements have become increasingly popular around the world. Vitamin tonics consist of various forms of vitamin supplements and are used by people all over the world to top up their dietary vitamin intake.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11168

The report examines every aspect of the global vitamin tonics market and presents the competitive and commercial dynamics of the market. Reliable analysis tools such as SWOT analysis and Porter’s five forces analysis have been used to arrive at detailed conclusions about every aspect of the global vitamin tonics market. The drivers and restraints and key segments of the vitamin tonics market, as well as the major companies operating in it, have been profiled in the report.

Global Vitamin Tonics Market: Drivers and Restraints

The increasing health consciousness among the global population is the primary driver of the global vitamin tonics market. As urbanization carries on at peak rates around the world, an increasing pool of the global population finds it difficult to spend enough time to cook an elaborate meal. This can result in several dietary disorders, since the nutritional requirements are often not met. Vitamin tonics are of immense help to such individuals, thus driving the demand in the global market. This also ties in with the general trend of rising preference for preventive medicine over curative, with vitamin tonics helping consumers avoid several possible diseases due to the varied functions performed by vitamins.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/vitamin-tonics-market.html

Despite the risk of overconsumption of vitamins, vitamin tonics are usually available to the general public without prescriptions, since they are classified as a dietary supplement. This has significantly driven the global vitamin tonics market, since the products can be purchased easily. The increasing sale of nutritional supplements on online portals has also been a major factor propelling the global vitamin tonics market.

Companies operating in the global vitamin tonics market have capitalized on the rising awareness among the global population by conducting several awareness programs about vitamin tonics. This has further boosted the prospects of the global vitamin tonics market.

Global Vitamin Tonics Market: Regional Overview

Regionally, North America is the largest market for vitamin tonics. The large demand for vitamin tonics in the region is due to the high rate of urbanization in countries such as the U.S., as well as the high medical awareness among the general population. However, the dominant share of North America is being slowly eroded by emerging regions such as Asia Pacific and Latin America. The increasing urbanization in these regions is giving rise to conditions due to which the vitamin tonics market has flourished in North America. This has also prompted several major players in the global vitamin tonics market to shift their focus toward Asia Pacific.

[lussi113]

Global Neurovascular stent retriever technology market- Evolving Industry Trends and Insights 2016 - 2024

According to WHO, there are 15 million people across the globe suffering from stroke each year. The incidence of obesity and diabetes has increased over the years and is responsible for the rising prevalence of strokes. Neurovascular stent retriever technology finds application in medical equipment used for the treatment of strokes. The American Heart Association and the American Stroke Association recommend the use of neurovascular stent retrievers for the treatment of strokes. This is driving the global neurovascular stent retriever technology market.

The global neurovascular stent retriever technology market is expected to witness a significant growth in the coming years owing to their use in the treatment of even the most serious cases of stroke with thromboembolic occlusion. The report segments the global neurovascular stent retriever technology market on the basis of technology, geography, and product. The major technologies studied in the report are embolization and coiling, neurothrombectomy, carotid artery angioplasty and stenting, and supporting technologies. The segmentation of the market is done so as to enable a detailed understanding of the performance of each segment of the global neurovascular stent retriever technology market.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11195

The report is compiled through extensive primary research, including surveys, interviews, and observations of expert analysts. Secondary research methods that make use of trade journals, industry databases, and paid sources are also used. The report includes details about the competitive landscape of the global neurovascular stent retriever technology market and profiles key players operating in the market.

Overview of the Neurovascular Stent Retriever Technology Market

Technological innovations and advancements in neurovascular stent retriever technology are driving the market. Advancements in neurovascular stent retriever technology are encouraged by various governments, especially in developed countries. This is because there has been a notable improvement in patients owing to the use of neurovascular stent retrievers, thus gaining government support. Moreover, the sedentary lifestyle and unhealthy eating habits of people worldwide are also boosting the global neurovascular stent retriever technology market. However, a dearth of skilled neurosurgeons, coupled with the high level of complexity involved with neurological surgeries, is hampering the growth of the market.

The global neurovascular stent retriever technology market is segmented on the basis of product into snares, suction and aspiration devices, flow diversion devices, embolic coils, clot retrievers, microcatheters, cerebral balloon angioplasty and stenting systems, support devices, embolic protection systems, and carotid artery stents.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/neurovascular-stent-retrievers-market.html

By geography, North America leads in the global neurovascular stent retriever technology market owing to the easy accessibility to advanced healthcare options in the region. Favorable reimbursement policies and a strong presence of neurovascular stent retriever device manufacturers in North America are boosting the growth of the market in the region. Significant investments in research and development activities are also helping the market’s growth. Europe and Asia Pacific are the second and the third largest regional segments in the market. The market in Asia Pacific is expected to grow in the coming years due to the dynamic economies of India and China and the rising cases of strokes in the region. The increasing ability of the consumers in the region to afford advanced medical treatment methods is also behind the growth of the region in the neurovascular stent retriever technology market.

Companies Mentioned in the Report

The report profiles the key players operating in the global neurovascular stent retriever technology market. The business and financial overviews of each of the companies are given. The challenges faced by the companies and the strategies adopted by them to stay at the forefront of the market are also given in the report. By offering details such as a company’s recent developments and product history, the report attempts to enlighten readers, helping them gain a competitive edge. The key players in the market are: Stryker, Meril Life Science Pvt .Ltd., Nitinol Devices & Components, Inc., Advent Devices Pvt. Ltd, Medtronic Plc, Norman Noble, INC., Hobbs Medical IN, STI Laser Industries, Ltd., and Akron Inc.

[lussi113]

Allergy Treatment Market- Rise in the global population suffering from different types of allergies drive the market

Global Allergy Treatment Market: Overview

Over the last few decades, there has been a dramatic rise in the prevalence of allergic diseases. According to the World Allergy Organization, an estimated 30% to 40% of the global population suffered from some form of allergic condition in 2011. The World Health Organization also stated that currently approximately 235 million people across the globe have asthma and another 100 million have rhinitis. Respiratory allergies have become the most common chronic disease among young adults and adolescents. This development has provided momentum to the global allergy treatment market.

Major types of allergies caused by food, drugs, insects, or the surrounding environment include rhinitis, conjunctivitis, eczema, and asthma. These allergies can be treated through either immunotherapy or anti-allergy medications such as corticosteroids, antihistamines, mast cell stabilizers, and decongestants. Clinics, hospitals, homes, and medical stores are the most preferred settings for the treatment of allergy.

The report offers in-depth information pertaining to the global allergy treatment market. The key drivers and challenges, the leading segments and sub-segments, and the threats and opportunities in the market have been determined and examined in detail. An exhaustive overview of the industrial structure, value chain, scope, and dynamics has been included in the study, along with a dedicated section on the vendor landscape. Prominent players competing at a global and regional level have been identified and a review of each company has been provided for a clearer understanding of the degree of competition.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11357

Global Allergy Treatment Market: Key Trends and Opportunities

A number of small and major factors is fueling the global allergy treatment market. Rise in the global population suffering from different types of allergies is a major factor driving the market. Changes in lifestyle and dietary habits, increase in environmental pollution, growing demand for advanced therapies targeted at allergy treatment, rising government initiatives, and a surge in research and development activities have also propelled the allergy treatment market.

Increase in alliances among leading players is another key factor that has augmented the global allergy treatment market. Allergy Therapeutics, a UK-based pharmaceutical company, acquired Spain-based Alerpharma S.A. in 2015 to expand its allergy immunotherapy product offerings. Later that year, Pfizer Inc. merged with Allergan plc to expand its share in the global drug industry.

On the other hand, side effects of immunotherapy and high cost of this treatment option act as major restraints of the global allergy treatment market.

View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/allergy-treatment-market.html

Global Allergy Treatment Market: Region wise Outlook

North America and Europe dominated the global allergy treatment market in the past few years due to escalating percentage of population suffering from allergies of the skin, eyes, and respiratory system. In addition, presence of developed health care, rise in environmental pollution, and increase in demand for immunotherapy in the treatment of allergies have accelerated the growth of the allergy treatment markets in these two regions. Asia Pacific is likely to emerge as one of the strongest contenders in the allergy treatment market in the next few years due to the rising allergic patient population pool. Moreover, rapid development of health care infrastructure, growing awareness about the availability of advanced immunotherapy for the treatment various types of allergies, and the surge in government expenditure in the health care sector are anticipated to contribute to the growth of the Asia Pacific allergy treatment market.

The most promising players in the global allergy treatment market include Allergy Therapeutics, Meda Pharmaceuticals, Inc., Allergan plc, Schering-Plough Corporation, Alerpharma S.A., McNeil Consumer Healthcare, Allergopharma, Genentech, Inc., Allergon AB, Collegium Pharmaceutical, Inc., and Sepracor, Inc. These companies have been looking to enter into mergers and acquisitions in the allergy treatment market in order to expand their businesses.